SCHEMBL5207445

SCHEMBL5207445

CCOP(=O)(Cc1ccc(NC(=O)CCc2oc(-c3ccc(OC)cc3)nc2-c2ccc(Cl)cc2)cc1)OCC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.49
KMT2A Q03164 6/20 0.49
KDR P35968 1/20 0.49
TP53 P04637 1/20 0.49
MAPT P10636 5/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
CETP P11597 4/20 0.47
HPGD P15428 3/20 0.47
HSD17B10 Q99714 3/20 0.47
ALDH1A1 P00352 3/20 0.47
MAPK1 P28482 1/20 0.47
PTGES O14684 1/20 0.46
KDM4E B2RXH2 3/20 0.44
CACNA1B Q00975 2/20 0.44
APBA1 Q02410 2/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
RXFP1 Q9HBX9 3/20 0.43
THRB P10828 2/20 0.43
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5207604 0.91 TP53 (0.47) MEN1KMT2AKDRTP53MAPT
SCHEMBL5213177 0.89 MAPT (0.40) MEN1KMT2AKDRTP53MAPT
SCHEMBL5215008 0.89 MAPT (0.41) MEN1KMT2AKDRTP53MAPT
SCHEMBL5207021 0.88 MAPT (0.44) MEN1KMT2ATP53MAPTHPGD
SCHEMBL5211940 0.87 MAPT (0.45) MEN1KMT2ATP53MAPTSMN1; SMN2
SCHEMBL5211339 0.87 MAPT (0.47) MEN1KMT2ATP53MAPTSMN1; SMN2
SCHEMBL5207465 0.86 MAPT (0.44) MEN1KMT2ATP53MAPTSMN1; SMN2
SCHEMBL5214838 0.86 KDM4E (0.49) MEN1KMT2AKDRTP53MAPT
SCHEMBL5208944 0.85 HDAC1 (0.42) MEN1KMT2ATP53MAPTSMN1; SMN2
SCHEMBL5210833 0.85 MAPT (0.46) MEN1KMT2ATP53MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7183276-B2 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-27 US disclosed
US-20050090534-A1 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-28 US disclosed
EP-1486490-A1 AZOLE COMPOUNDS Takeda Chemical Industries, Ltd. (JP) 2004-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090534-A1 Azole compounds AHR, NR0B2, NR2C2 MEN1 1626/4885KMT2A 680/4885KDR 961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.